Intens Care Med:危重病人血清乳酸的预后价值

2018-12-02 xing.T MedSci原创

由此可见,即使在对混杂因素进行校正之后,较低的Δ24Lac也与危重病人的不良结局密切相关。Δ24Lac可能成为危重病危险分层的独立、易得和重要的指标参数。

据报道,乳酸盐浓度随时间的变化与脓毒症患者的存活率相关。近日,危重病医学领域权威杂志Intensive Care Medicine上发表了一篇研究文章,研究人员旨在评估入院后24小时乳酸盐浓度的变化值(Δ24Lac)对重症监护室(ICU)的危重病人短期和长期预后的影响。

该研究总共对2119名入住德国ICU的患者进行了26285次乳酸测量。纳入标准是入院时乳酸盐浓度高于2.0mmol/L. 使用第1天和第2天的最大乳酸浓度来计算Δ24Lac。回顾性地进行患者随访。研究人员分析了Δ24Lac与院内和长期死亡率之间的关系。通过Youden指数计算最佳截止值。

研究人员发现Δ24Lac较低的患者年龄相近,但临床病情较重。作为连续变量,较高的Δ24Lac患者院内死亡率降低(每1%Δ24Lac; HR为0.987;95%CI为0.985-0.990;p<0.001),并且最佳Δ24Lac截止值计算为19%。Δ24Lac≤19%与住院时间(15% vs. 43%; OR为4.11; 95%CI为3.23-5.21; p<0.001)和长期死亡率(HR为1.54; 95%CI为1.28-1.87; p<0.001)增加有关,即使在校正APACHE II后,也需要儿茶酚胺和插管。研究人员将256例Δ24Lac≤19%的患者匹配校正了APACHE II评分、基线乳酸水平和性别的Δ24Lac>19%对照病例发现:Δ24Lac≤19%与较低的住院和长期生存率相关。

由此可见,即使在对混杂因素进行校正之后,较低的Δ24Lac也与危重病人的不良结局密切相关。Δ24Lac可能成为危重病危险分层的独立、易得和重要的指标参数。

原始出处:

Maryna Masyuk,et al.Prognostic relevance of serum lactate kinetics in critically ill patients.Intensive Care Medicine.2018. http://icmjournal.esicm.org/journals/abstract.html?v=0&j=134&i=0&a=5475_10.1007_s00134-018-5475-3&doi=

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038992, encodeId=7af62038992a8, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Apr 07 10:14:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690469, encodeId=465d169046934, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Thu Jul 04 23:14:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385218, encodeId=934913852185e, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533249, encodeId=692215332499d, content=<a href='/topic/show?id=c3c236e5229' target=_blank style='color:#2F92EE;'>#危重病人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36752, encryptionId=c3c236e5229, topicName=危重病人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53bc12401014, createdName=listen322, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609361, encodeId=302f1609361c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038992, encodeId=7af62038992a8, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Apr 07 10:14:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690469, encodeId=465d169046934, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Thu Jul 04 23:14:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385218, encodeId=934913852185e, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533249, encodeId=692215332499d, content=<a href='/topic/show?id=c3c236e5229' target=_blank style='color:#2F92EE;'>#危重病人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36752, encryptionId=c3c236e5229, topicName=危重病人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53bc12401014, createdName=listen322, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609361, encodeId=302f1609361c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2038992, encodeId=7af62038992a8, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Apr 07 10:14:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690469, encodeId=465d169046934, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Thu Jul 04 23:14:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385218, encodeId=934913852185e, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533249, encodeId=692215332499d, content=<a href='/topic/show?id=c3c236e5229' target=_blank style='color:#2F92EE;'>#危重病人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36752, encryptionId=c3c236e5229, topicName=危重病人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53bc12401014, createdName=listen322, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609361, encodeId=302f1609361c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2038992, encodeId=7af62038992a8, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Apr 07 10:14:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690469, encodeId=465d169046934, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Thu Jul 04 23:14:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385218, encodeId=934913852185e, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533249, encodeId=692215332499d, content=<a href='/topic/show?id=c3c236e5229' target=_blank style='color:#2F92EE;'>#危重病人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36752, encryptionId=c3c236e5229, topicName=危重病人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53bc12401014, createdName=listen322, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609361, encodeId=302f1609361c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2038992, encodeId=7af62038992a8, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Apr 07 10:14:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690469, encodeId=465d169046934, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Thu Jul 04 23:14:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385218, encodeId=934913852185e, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533249, encodeId=692215332499d, content=<a href='/topic/show?id=c3c236e5229' target=_blank style='color:#2F92EE;'>#危重病人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36752, encryptionId=c3c236e5229, topicName=危重病人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53bc12401014, createdName=listen322, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609361, encodeId=302f1609361c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Dec 04 01:14:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2018-12-04 hb2008ye

相关资讯

Intens Care Med:非药物干预在降低危重病人谵妄发生率和持续时间方面的疗效分析

由此可见,目前的证据不支持使用非药物干预措施来降低危重病人的谵妄发生率和持续时间。未来的研究应该考虑精心设计和充分描述的多种组合的干预措施,并充分定义结局指标。

Resp Care:危重病患者预先使用高流量鼻导管

建议使用高流量鼻导管(HFNC)可能是急性缺氧性呼吸衰竭患者的一线治疗方法。本研究的目的是确定拟使用HFNC是否减少ICU患者的非计划插管和不良结果的发生。

Crit Care:危重病人经皮气管切开术是选择垂直还是横向皮肤切口?

由此可见,这项回顾性研究显示重症患者PT的横向皮肤切口导致整体并发症显著减少,尤其是气管切开术部位的溃疡。

Intens Care Med:尿肌酐排泄与危重病人的短期和长期死亡率有关

由此可见,在没有严重肾功能不全的ICU患者中,较低的尿肌酐排泄与短期和长期死亡率相关,而与年龄、性别、肾功能和疾病特征无关,其强调了肌肉质量可作为死亡率的危险因素,而UCE可作为相关生物标志物。

中国循环杂志:替格瑞洛负荷后急性左心衰8例报告,危重病人或许谨慎使用?

新疆医科大学附属中医医院和上海交通大学附属第九医院的三位医生,报告了8个急性冠状动脉综合征(ACS)患者服用负荷量替格瑞洛180 mg出现急性左心衰竭的病例。

Intens Care Med:危重病人预防应激性溃疡的疗效和安全性分析!

由此可见,该研究的结果提供了中等质量的证据表明PPIs是预防CIB最有效的药物,但它们可能增加肺炎的风险。利弊平衡使得SUP的常规使用受到了质疑。